Efficacy and safety of huanglian wendan decoction as an adjuvant therapy for metabolic syndrome: a systematic review and meta-analysis
Abstract
Background: Metabolic syndrome (MetS) is a prevalent metabolic disorder with a rising global prevalence, serving as a risk factor for cardiovascular disease and type 2 diabetes. Huanglian Wendan Decoction, a commonly used formula in traditional Chinese medicine, has increasingly been used to treat MetS. This study aims to evaluate the efficacy and safety of Huanglian Wendan Decoction as an adjunctive therapy for MetS.
Objective: This meta-analysis aims to systematically evaluate the efficacy and safety of Huanglian Wendan Decoction in treating metabolic syndrome, thereby providing new approaches and insights for its management.
Methods: Literature searches were conducted using English-language databases (PubMed, Web of Science, Embase, and the Cochrane Library) and Chinese databases (China National Knowledge Infrastructure Wanfang, the VIP Chinese Science Journal Database, and the Chinese Biomedical Literature Database). The search period extended through 1 October 2025. Data were analyzed using RevMan 5.3 and Stata 17.0. The study protocol is registered in PROSPERO (registration number: CRD420251151304).
Results: A total of 17 randomized controlled trials, involving 1,549 patients, were ultimately included. Huanglian Wendan Decoction combined with conventional treatment for MetS significantly improved waist circumference (WC) (MD = -1.82 cm, 95% CI:-2.53 to -1.12, P < 0.00001), body mass index (BMI) (MD = -0.76 kg/m2, 95% CI: -0.99 to -0.54, P < 0.00001), systolic blood…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,549 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.